Department of Surgery, CWM Hospital, 1 Waimanu Road, Suva, Fiji.
Fiji Office, Korea International Cooperation Agency, 91 Gordon St., Suva, Fiji.
Int J Environ Res Public Health. 2022 Feb 7;19(3):1861. doi: 10.3390/ijerph19031861.
Mumps remains endemic in Fiji, with 7802 cases reported between 2016 and 2018. The introduction of mumps vaccination has been discouraged due to perceptions of mumps as a self-limited disease and the perceived high cost of mumps vaccines. We estimated the benefits and costs of introducing a mumps vaccination program in Fiji. First, we estimated the burden of mumps and mumps-related complications in Fiji based on the reported cases in the Fiji National Notifiable Disease Surveillance System between 2016 and 2018. We then developed a static simulation model with stable mumps herd immunity after routine measles-mumps-rubella (MMR) vaccination. Finally, we compared the estimated economic burden of mumps with current MR vaccination and the assumptive burden of the stable-state simulation model after routine MMR vaccination. The benefit-cost ratios (BCRs) were 2.65 from the taxpayer view and 3.00 from the societal view. A probabilistic sensitivity analysis indicated that the 1st and 99th percentiles of BCRs were 1.4 and 5.2 from the taxpayer's perspective and 1.5 and 6.1 from the societal perspective. From both the taxpayer and societal perspectives, the probability of BCRs greater than 1.0 was 100%. A routine MMR program has value for money from both the taxpayer and societal perspectives. MMR vaccination should be urgently introduced in Fiji.
在斐济，腮腺炎仍然流行，2016 年至 2018 年期间报告了 7802 例病例。由于认为腮腺炎是一种自限性疾病，以及认为腮腺炎疫苗成本高，因此不鼓励引入腮腺炎疫苗接种。我们估计在斐济引入腮腺炎疫苗接种计划的收益和成本。首先，我们根据 2016 年至 2018 年斐济国家法定传染病监测系统报告的病例，估计了腮腺炎在斐济的负担和与腮腺炎相关的并发症。然后，我们开发了一个静态模拟模型，在常规麻疹-腮腺炎-风疹（MMR）疫苗接种后具有稳定的腮腺炎群体免疫力。最后，我们将腮腺炎的估计经济负担与当前 MR 疫苗接种以及常规 MMR 疫苗接种后的稳定状态模拟假设负担进行了比较。从纳税人的角度来看，效益成本比（BCR）为 2.65，从社会的角度来看，BCR 为 3.00。概率敏感性分析表明，从纳税人的角度来看，BCR 的第 1 和第 99 个百分位数分别为 1.4 和 5.2，从社会的角度来看，BCR 的第 1 和第 99 个百分位数分别为 1.5 和 6.1。从纳税人角度和社会角度来看，BCR 大于 1.0 的概率均为 100%。从纳税人角度和社会角度来看，常规 MMR 计划都具有成本效益。在斐济，应紧急引入 MMR 疫苗接种。
